Introduction {#sec1}
============

Histone-deacetylase-associated (HDAC-associated) DNA-binding transcription factors, including REST (also known as neuron-restrictive silencer factor \[NRSF\]) and coregulators such as the nuclear receptor corepressor (NCOR/Ncor1) and silencing mediator of retinoic acid and thyroid hormone receptors (SMRT/Ncor2), have been shown to be essential regulators of neural proliferation and differentiation during brain development, as they actively repress lineage-characteristic gene expression and are required for self-renewal or progression of cell fate specification ([@bib1; @bib4; @bib17; @bib21; @bib23; @bib30; @bib36; @bib50]). Mammalian HDACs can be divided into several classes, with the class I HDACs most strongly associated with NCOR and SMRT ([@bib53]). NCOR and/or SMRT-HDAC complexes regulate histone modifications occurring at single lysines of histone tails that seem to display progenitor-specific signatures ([@bib47]). These modified lysines in turn function as molecular beacons recruiting specific complexes for regulation of gene expression ([@bib38; @bib42]). Studies using inhibitors of HDACs, including valproic acid (VPA), have established that such compounds can affect the differentiation of embryonic and adult neural progenitors both negatively and positively and also exert toxic effects on neuroectodermal cells ([@bib19; @bib29; @bib35; @bib43]). Genetic models of HDAC1 and HDAC2 ablation also support roles for class I HDACs in regulating forebrain neural progenitor characteristics, although the roles for individual HDACs remain unclear ([@bib37; @bib54]).

Despite the neurodevelopmental phenotypes and neural progenitor aberrations of mice harboring genetic deletions of *Ncor* versus *Smrt* being distinct ([@bib17; @bib20; @bib21]), functional and nonredundant specificity regarding the associated HDACs is not well understood ([@bib38]). HDAC activity has been shown to both be required and repressive for neurogenesis ([@bib19; @bib37]). Likewise, HDAC activity can be required for oligodendrocyte differentiation and proper myelination ([@bib54]). However, HDAC inhibitors such as VPA have also been shown to have positive effects on oligodendrocyte generation and function ([@bib32]), and the alleviation of transcription factors associated with HDAC complexes, such as REST (NRSF), results in increased expression of oligodendrocyte genes ([@bib9]). Only a few studies have addressed the roles for individual HDACs and histone acetyl transferases (HATs) in oligodendrocyte differentiation of embryonic forebrain progenitors using genetic mouse models ([@bib50; @bib54]). The deletion of *Hdac1* or *Hdac2* individually in NSCs only had limited effects, while simultaneous deletion of the two factors resulted in a loss of markers of oligodendrocyte differentiation in cortical progenitors ([@bib54]). Paradoxically, genetic and RNA knockdown of the HAT *Cbp* (also known as *Crebbp*) in the embryonic forebrain also resulted in decreased expression of oligodendrocyte markers in cortical NSCs, and *Cbp* haploinsufficiency leads to aberrant development of the corpus callosum ([@bib50]).

To elucidate the roles for these factors in differentiation of cortical progenitors, we undertook an investigation of the functional roles for class I HDACs and nuclear receptor corepressors in the enforcement of NSC repression checkpoints that are subsequently released during differentiation to neurons and glia. By analysis of NSCs derived from rodents with gene deletions and/or specific RNA knockdown in wild-type primary-derived NSCs, we have revealed a series of distinct functional roles for the class I HDACs, HDAC2, and HDAC3, alone and in concert with NCOR or SMRT in the regulation of NSC differentiation into neurons and oligodendrocytes.

Results {#sec2}
=======

HDAC2 and HDAC3 Show Both Unique and Overlapping Binding to Promoter Regions of Genes Associated with Neuronal and Oligodendrocyte Differentiation {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------------------------

To investigate specific roles for HDAC2 and HDAC3, we performed chromatin immunoprecipitation sequencing (ChIP-seq) (Gene Expression Omnibus \[GEO\] accession [GSE57232](ncbi-geo:GSE57232){#intref0010}; see [@bib12; @bib15]) and subsequent single-gene ChIP analysis (see [@bib31]) in neural stem cells (NSCs) derived from embryonic cortices of rats at embryonic day 15 (E15), which produce HDAC2 and HDAC3, but not HDAC1 ([Figure 1](#fig1){ref-type="fig"}C). HDAC2 and HDAC3 were determined to be present in the vicinity of a number of genes associated with transcriptional regulation of differentiation ([Figure 1](#fig1){ref-type="fig"}A). Several of the regions identified by ChIP-seq were confirmed by subsequent single-gene ChIP-quantitative PCR (ChIP-qPCR) experiments that demonstrated that HDAC2 and HDAC3 could bind both in an overlapping and distinct fashion near genes associated with development and differentiation, including *Cebpb* (C/EBPβ), *Hoxd4*, *Ovol2*, and *Zfp7* ([Figure 1](#fig1){ref-type="fig"}A; data not shown). A more detailed analysis revealed differences in enrichment at certain genes critically involved in NSC differentiation. Whereas a significant enrichment of HDAC3 was found on the promoters of both *Pax6* and *Sox8*, genes encoding transcription factors associated with neuronal and oligodendrocyte differentiation of NSCs, increased enrichment of HDAC2 was only found on the *Sox8* promoter ([Figure 1](#fig1){ref-type="fig"}B). This observation was of particular interest due to a previous report demonstrating that class I HDACs, including HDAC2, are essential for proper progression of embryonic oligodendrocyte development ([@bib54]).

Similar to SMRT, HDAC3 Represses Neuronal Genes in Embryonic NSCs {#sec2.2}
-----------------------------------------------------------------

While previous analyses of the functional roles for HDAC1 and HDAC2 by genetic mouse models have confirmed redundant roles for the two factors in embryonic development of the nervous system, our ChIP analysis suggested that there could be functional differences between HDAC2 and HDAC3 in embryonic NSCs. To examine the individual role(s) of these class I HDACs in NSCs, specific small interference RNA (siRNA) pools were used to rapidly and conditionally knockdown *Hdac2* and *Hdac3* mRNA in the cortically derived NSCs (see [Figures S1](#app3){ref-type="sec"}A and S1B available online for efficiency of the siRNAs). NSCs transfected with siHDAC3 or a combination of siHDAC2 and siHDAC3 showed global hyperacetylation of H3K9 ([Figure 1](#fig1){ref-type="fig"}E) and a significant increase in TuJ1-positive cells ([Figure 1](#fig1){ref-type="fig"}D), as well as an increased H3K9 acetylation on the well-established HDAC target *Bdnf* IV promoter as compared to control siRNA ([Figure 1](#fig1){ref-type="fig"}F). In contrast, transfection of siHDAC2 had no significant effect on these parameters ([Figures 1](#fig1){ref-type="fig"}D--1F). Analysis of gene expression by quantitative RT-PCR (qRT-PCR) showed that siHDAC2 treatment had no significant effect on *Bdnf* mRNA levels in NSCs, whereas siHDAC3 delivery alone was sufficient to induce a significant increase in *Bdnf* gene expression ([Figure 1](#fig1){ref-type="fig"}G). As the gene encoding TUBB3, the protein detected by the antibody TuJ1, is a direct target for the HDAC-associated repressor REST, it is possible that the increase in TuJ1-positive cells could be due to a direct regulation and increased acetylation at the *Tubb3* gene. We however also noted an increase in expression of the proneuronal gene *Neurog2* 6--24 hr after siHDAC3 delivery (data not shown), pointing to multiple putative mechanisms that could underlie increased neuronal differentiation and survival after siHDAC3 delivery. Together, these results demonstrate that HDAC3, but not HDAC2, is a nonredundant repressor of H3K9 acetylation, *Bdnf* gene expression, and neuronal differentiation in cortical NSCs.

To shed further light on the mechanisms underlying the functional specificity of HDAC2 and HDAC3, we turned to the closely associated nuclear receptors NCOR and SMRT. These HDAC-associated corepressors have in spite of their sequence homology previously been shown to play distinct functional roles in NSCs as spontaneous neuronal and astrocytic differentiation has been noted only in NSCs derived from *Smrt*-deficient mice, while only astrocytic and no neuronal differentiation has been reported in NSCs from *Ncor*-deficient or double-heterozygote mice ([@bib17; @bib21]). ChIP analysis revealed that both SMRT and HDAC3 were enriched at the *Bdnf* IV promoter, and qRT-PCR investigation of *Bdnf* gene expression levels in *Smrt*^−/−^ NSCs revealed a significant (\>4-fold) increase compared to wild-type cells ([Figures 1](#fig1){ref-type="fig"}H and 1I). In contrast, *Bdnf* mRNA levels in *Ncor*^−/−^ NSCs, which do not differentiate down the neuronal pathway, remained unchanged (data not shown; see further below). This result suggests that HDAC3, rather than HDAC2, is involved in at least a subset of the critical SMRT-mediated repressive events in NSCs.

Absence of the T3-Associated Corepressor NCOR Promotes Oligodendrocyte-Associated Gene Expression {#sec2.3}
-------------------------------------------------------------------------------------------------

NSCs derived from mice gene-deleted for either *Ncor* or *Smrt*, or from double-heterozygote animals, spontaneously differentiate into astrocytes, suggesting that regulation of this pathway depends on proper gene dosage of both *Ncor* and *Smrt* ([@bib17; @bib21]). Interestingly, a substantial subset of the *Ncor*^−/−^ NSCs display neither the astrocytic marker GFAP nor the stem cell marker nestin or neuronal marker TuJ1 ([@bib17]), suggesting the possibility that NCOR represses additional NSC fates. Indeed, gene expression profiling analysis by microarrays of *Ncor*^−/−^ NSCs after 4 days in vitro (DIV) revealed a dramatic upregulation of several oligodendrocyte (OL)-associated genes, including myelin-basic protein (*Mbp*), myelin proteolipid protein (*Plp*), *beta tubulin 4*, and *Nkx2.2*, as well as early pan-glial markers such as *S100β*, whereas no significant upregulation of neuronal genes was detected ([Figure 2](#fig2){ref-type="fig"}B; [@bib17]). In contrast, gene expression profiling of *Smrt*^−/−^ NSCs or NSCs treated with the HDAC inhibitor valproic acid (VPA) failed to detect any upregulation of OL-associated genes ([Figure S2](#app3){ref-type="sec"}A; Figure S4 in [@bib21]). Detailed analysis revealed that approximately 18% of *Ncor*^−/−^ NSCs stained positive for the archetypical OL marker MBP and presented morphology typical for immature oligodendrocytes, whereas wild-type cells did not ([Figures 2](#fig2){ref-type="fig"}A and 2C). qRT-PCR experiments confirmed the upregulation of MBP expression in *Ncor*^−/−^ as compared to wild-type (WT) NSCs at the mRNA level ([Figure 2](#fig2){ref-type="fig"}D). These results indicate that NCOR plays a critical role in a repression checkpoint of OL differentiation in embryonic multipotent NSCs and that absence of NCOR initiates specification into OL cell types.

HDAC Inhibitors Promote OL Differentiation in Combination with T3 Stimulation, but Not Alone {#sec2.4}
--------------------------------------------------------------------------------------------

NCOR was originally identified as interacting with the unliganded T3 receptor (T3R) to repress gene transcription. Indeed, it has been firmly established that T3 stimulation leads to transcriptional activation of its target genes by initiating removal of transcriptional corepressors such as NCOR from T3R, resulting in recruitment of coactivator proteins ([@bib3; @bib16; @bib38]). As T3 plays an essential role during OL development ([@bib5]), and can lead to the specification of embryonic NSCs into the oligodendrocyte lineage ([@bib22]), we reasoned that NCOR may repress OL differentiation through its role as a T3R corepressor. Treatment of wild-type embryonic NSCs with T3 induced OL differentiation in NSC cultures, as assessed by morphology and the upregulation of OL-characteristic genes, including *Mbp* and *Plp*, and early immunocytochemical markers, including RIP, at both the mRNA and protein level ([Figures 2](#fig2){ref-type="fig"}E and 2F), in accordance with previous reports ([@bib22]).

While conventional models would associate NCOR-mediated repression with HDAC repressor function, alleviation of HDAC activity has paradoxically mostly been associated with inhibition of OL differentiation ([Figure S2](#app3){ref-type="sec"}A) ([@bib8; @bib35; @bib54]), suggesting that HDACs are rather required for OL differentiation. To investigate whether T3 modulated the effects of HDAC inhibition on the OL lineage, embryonic NSCs were treated with T3 and VPA (0.5 mM), either alone or in combination. While T3 alone resulted in promotion of OL differentiation and gene expression, the expression of OL genes did not change in response to VPA alone ([Figure 2](#fig2){ref-type="fig"}E). In contrast, cotreatment of the NSCs with both T3 and VPA resulted in increased expression of *Mbp* and *Plp* after 7 DIV ([Figure 2](#fig2){ref-type="fig"}E). We also observed an increase in late markers of OL differentiation as compared to early markers in cells treated with both T3 and VPA at 7 DIV. Specifically, we found an increase in the number of cells displaying the late marker MBP double labeled with the early OL marker RIP, from 29% ± 3.2 in control conditions to 77% ± 3.4 in T3+VPA conditions ([Figures 2](#fig2){ref-type="fig"}F and 2G). In accordance with the increased MBP/RIP ratio and the possible increase in maturation, T3+VPA cotreatment resulted in morphological signs of late OL differentiation, including formation of myelin plaque-like structures ([Figure 2](#fig2){ref-type="fig"}F) and an increase in the average oligodendrocyte radius ([Figure 2](#fig2){ref-type="fig"}H). Notably, VPA treatment alone increased MBP immunoreactivity and the average oligodendrocyte radius in a very small subset of cells ([Figure 2](#fig2){ref-type="fig"}G and 2H), but it had no effect compared to the vehicle (EtOH) on the actual number of immature oligodendrocytes ([Figures S2](#app3){ref-type="sec"}B and S2C).

HDAC2 Mediates Specific Control of *Sox10* Expression in OL Differentiation {#sec2.5}
---------------------------------------------------------------------------

The ChIP-seq analysis revealed binding of HDAC2 to a subset of genes associated with oligodendrocyte differentiation, including *Sox8*, suggesting that HDAC2 might play a role in the oligodendrocyte lineage. Thus, we differentiated NSCs in the presence or absence of T3 for 3 days, lipofected the cells with siRNAs against *Hdac2* and/or *Hdac3*, and then assessed the OL differentiation at 3 days after siRNA transfection (DAT) (see [Figure S2](#app3){ref-type="sec"}D for scheme). In the absence of T3, no significant effects on the expression of genes associated with OL and glial development were seen after siRNA knockdown of *Hdac2* or *Hdac3* alone or in combination at 3 DAT ([Figures 3](#fig3){ref-type="fig"}A and 3B; data not shown). However, in the presence of T3, there was a significant upregulation of MBP and PLP expression following transfection with siHDAC2 or siHDAC3 ([Figures 3](#fig3){ref-type="fig"}A--3C), although we noted that the predominant effects on the expression of these genes were mediated by T3. Moreover, knockdown of *Hdac2* but not *Hdac3* in the oligodendrocyte cell lines Oli-neu ([@bib25]) and CG4 ([@bib33]) also induced an increased expression of oligodendrocyte markers as MBP, CNPase, and PLP ([Figures 3](#fig3){ref-type="fig"}D and 3E; [Figures S3](#app3){ref-type="sec"}A, S3B, and S3H), which in the Oli-neu cells was accompanied by a dramatic change of morphology ([Figure 3](#fig3){ref-type="fig"}E; [Figure S3](#app3){ref-type="sec"}A). These results suggest that the effects of VPA on OL differentiation by T3 are at least partially dependent on HDAC2 activity.

We next performed a functional screen to compare gene expression profiles of T3-treated NSCs to NSCs treated with VPA only or with VPA+T3, with particular attention to genes implicated in glial differentiation. While the expression of many OL-characteristic genes were influenced by T3 but not VPA, expression of the OL-associated transcription factor *Sox10* was specifically increased 4-fold after VPA and VPA+T3 treatment, but unaffected by T3 alone ([Figure 4](#fig4){ref-type="fig"}A). Interestingly, *Sox10* expression was increased by siHDAC2 upon T3 treatment ([Figure 4](#fig4){ref-type="fig"}B). In contrast, *Sox10* mRNA levels were not affected by siHDAC3, by T3 treatment, or in *Ncor*^−/−^ or *Smrt*^−/−^ NSCs ([Figures 2](#fig2){ref-type="fig"}B, [4](#fig4){ref-type="fig"}A, and 4B; [@bib21]). In accordance with this result, *Sox10* mRNA levels were also increased upon *Hdac2*, but not *Hdac3* knockdown in Oli-neu cells (data not shown; see further below). A similar trend was seen for *Sox8*, detected as a direct HDAC2 target in the ChIP-seq experiments ([Figure 1](#fig1){ref-type="fig"}B). Transcriptional inhibitors of OL differentiation, such as *Hes5*, were not affected by treatment with VPA alone in the NSCs ([Figure 4](#fig4){ref-type="fig"}C), in contrast to what has been observed in postnatal oligodendrocyte precursor cells (OPCs) ([@bib34; @bib46]).

SOX10 is required for terminal OL differentiation as null mutant mice for this SoxE protein generate normal numbers of OL progenitors that fail to terminally differentiate ([@bib48]). To test whether SOX10 could mediate the additive effects of VPA in T3-mediated OL differentiation of embryonic NSCs, NSCs were differentiated in the presence of VPA and/or T3 and lipofected at 3 days with siRNA against *Sox10* ([@bib41]) ([Figure S2](#app3){ref-type="sec"}D; [Figure S1](#app3){ref-type="sec"}B for efficiency of the siRNA). Gene expression was then analyzed 3 DAT. Knockdown of *Sox10* partially prevented the upregulation of MBP and PLP and blocked the terminal OL differentiation induced by the cotreatment of VPA and T3 at 3 DAT ([Figures 4](#fig4){ref-type="fig"}D and 4E). *Sox10* knockdown also reduced the mRNA levels of *Cnpase* and *Sox8* at 3 DAT, but importantly did not affect earlier markers, including *Sox9*, in differentiating NSCs ([Figure 4](#fig4){ref-type="fig"}E). We conclude that SOX10 is required for the proper OL differentiation effects observed when treating NSCs with VPA or siHDAC2 and T3.

To investigate specific roles for class I HDACs in the VPA-mediated potentiation of OL differentiation of NSCs, we next investigated the presence of HDAC2 and HDAC3 at previously characterized regulatory regions of *Mbp* ([@bib11]) and *Sox10* ([@bib52]) in the embryonic NSCs ([Figure 5](#fig5){ref-type="fig"}A). ChIP-qPCR analysis indicated that while both HDAC2 and HDAC3 were present in the regulatory regions of the *Mbp* gene in NSCs and Oli-neu cells ([Figure 5](#fig5){ref-type="fig"}B; [Figure S3](#app3){ref-type="sec"}D), HDAC2 was specifically enriched in the U2 enhancer of *Sox10* ([Figure 5](#fig5){ref-type="fig"}B, left panel). This HDAC2 enrichment was observed both in comparison to other regions bound by HDAC2 as well as in comparison to the occupancy of HDAC3 at the same region ([Figure 5](#fig5){ref-type="fig"}B). Similar results were obtained in Oli-neu cells ([Figures S3](#app3){ref-type="sec"}C and S3F). Indeed, an analysis of the acetylation state of the regulatory regions of *Sox10* revealed relatively low acetylation levels of H3K14 and H4K16, but not H3K9, at the U2 enhancer in NSCs and to an extent also in the Oli-neu cells, strengthening the observation of increased HDAC2 occupancy at this specific enhancer ([Figure 5](#fig5){ref-type="fig"}C; [Figure S3](#app3){ref-type="sec"}E). The U2 enhancer is an element that previously has been shown to regulate *Sox10* expression specifically in the oligodendrocyte lineage starting at embryonic midgestation ([@bib28; @bib52]). Together with our data, this suggests that HDAC2 may be specifically required for *Sox10* gene regulation in early oligodendrocyte development. Class I HDACs and NCORs have been identified as binding partners of SOX2 ([@bib10]), and an in silico analysis revealed a putative binding site for SOX2 in the U2 enhancer of *Sox10* ([Figure S4](#app3){ref-type="sec"}). We therefore investigated whether this T3 and NCoR-independent HDAC2-mediated repression of *Sox10* could be mediated in association with SOX2. Indeed, we found a significant enrichment of SOX2 occupancy on the U2, but not U1, enhancer compared to control regions ([Figure 5](#fig5){ref-type="fig"}D; data not shown). siRNA-mediated knockdown of *Sox2*, however, did not result in any significantly increased expression of *Sox10* (data not shown), suggesting that other factors are sufficient to recruit HDAC2 to the U2 enhancer and mediate the essential repression.

*Sox10*, but Not HDACs, Is Required for Maintenance of the Differentiated State in Postnatal OL Progenitors {#sec2.6}
-----------------------------------------------------------------------------------------------------------

The differentiation of OPCs begins in early postnatal stages in the forebrain, although its peak occurs a few days later ([@bib51]). It is noteworthy that *Hdac2* expression has been reported to decrease in cells of the oligodendrocyte lineage at these stages ([@bib45]). Interestingly, we did not observe any morphological signs of premature differentiation of the proliferating postnatal CG4 upon siHDAC2 and/or siHDAC3 delivery (data not shown), in contrast to what we observed in embryonic Oli-neu cells or T3-treated NSCs ([Figure 2](#fig2){ref-type="fig"}; [Figure S3](#app3){ref-type="sec"}A). Moreover, although moderate increases in gene expression levels of *Mbp* and *Plp* were observed following transfection with siHDAC2 in the CG4 cells ([Figure S3](#app3){ref-type="sec"}H), these were found not to be associated with an siHDAC2-mediated *Sox10* derepression as *Sox10* levels were indeed rescued by siHDAC2, but *Mbp* and *Plp* expression levels were not in these cells ([Figure S3](#app3){ref-type="sec"}H; data not shown). These results suggested that SOX10 could play alternative roles at this late stage of OL differentiation. Intriguingly, *Sox10* siRNA delivery at this stage instead resulted in a dramatic increase in gene expression associated with the stem cell state ([@bib39; @bib44]), including *Sox2*, *Sox9*, *Sox8*, and *Hes5*, without affecting markers of neuronal differentiation ([Figure 5](#fig5){ref-type="fig"}E; data not shown). This result stands in sharp contrast to the mild effects of *Sox10* siRNA on the expression of these genes in NSCs and a reversible increase of *Sox9* expression in Oli-neu cells ([Figure 4](#fig4){ref-type="fig"}E; data not shown). Taken together, our observations suggest that *Sox10* expression is required for efficient progression of oligodendrocyte differentiation and expression of late OL characteristic genes and at a later stage serves to maintain the differentiated state and suppress the expression of genes associated with more undifferentiated progenitors and stem cells ([Figure 6](#fig6){ref-type="fig"}).

Discussion {#sec3}
==========

Transcriptional corepressors such as NCOR and SMRT have distinct roles in repressing differentiation in NSCs, and we therefore hypothesized that associated HDACs also have specific functions albeit the reports so far have been unclear. Here we demonstrate that whereas HDAC3 and SMRT, and not HDAC2 or NCoR, are part of a repression checkpoint for neuronal differentiation in embryonic NSCs, NCoR and HDAC2 constitute specific repressor checkpoints in control of oligodendrocyte differentiation ([Figure 6](#fig6){ref-type="fig"}). The mechanism by which HDAC2 inhibits oligodendrocyte differentiation is at least in part, via repression of the key transcription factor SOX10, coinciding with binding of HDAC2 to the SOX2-occupied U2 enhancer of the *Sox10* gene ([Figure 6](#fig6){ref-type="fig"}). Together, these data reveal nonredundant roles for class I HDACs and associated factors in NSC differentiation.

Our results suggest that specific HDACs play distinct roles in the differentiation of NSCs. Chemical or genetic ablation of class I HDAC activity have been reported to inhibit oligodendrocyte and Schwann cell differentiation and promote neuronal differentiation ([@bib8; @bib19; @bib35]). In these studies, HDACs are suggested to repress inhibitors of OL differentiation, thereby being required for proper oligodendrocyte differentiation. However, deletion of the HAT CREB-binding protein also results in decreased oligodendrocyte differentiation and corpus callosum deficits ([@bib50]), and HDACs have also been shown to be required for neurogenesis ([@bib37]), blurring a general consensus statement of the function of these factors in NSC differentiation. In the present study, loss of HDAC2 activity in the presence of T3 resulted in enhanced oligodendrocytic differentiation in embryonic cortical NSCs. Strikingly, HDAC2 does repress directly the key OL transcription factor *Sox10*, in contrast to the indirect effects of HDACs previously reported. Thus, the effects of HDAC inhibition on NSCs appear to be distinct depending on cell-type specificity, the temporal window of action, and the presence of additional factors. These cell-type and temporal specific effects of HDACs are in line with what has been reported for components of the NOTCH and WNT signaling, which can have both repressing and activating functions in oligodendrocyte development ([@bib40; @bib49]).

Class B1 Sox proteins such as SOX2 are established repressors of differentiation and required to retain stem cell characteristics during development and in the adult ([@bib2; @bib6; @bib10; @bib14]), but it has been shown that SOX2 can also act as a transcriptional activator in certain developmental contexts ([@bib18]). Our data on NCOR, HDAC2, and SOX10 suggest a transcriptional "transmission" mechanism where the appropriate "gear" controls the level of progenitor state and early and late progression of oligodendrocyte differentiation. In NSCs and embryonic OPCs, HDAC2 were found to bind to the critical U2 enhancer regulating *Sox10* in association with SOX2, and alleviation of HDAC2 led to an increase in *Sox10* expression. OLIG2 has recently been shown to activate the U2 enhancer ([@bib28]) and as such could also be a candidate for the upregulation of *Sox10* expression. Nevertheless, in contrast to SOX2 ([Figure 5](#fig5){ref-type="fig"}D), OLIG2 is present not only at the U2 enhancer in immature oligodendrocytes but also at the U1, U3, U4, and U5 *Sox10* enhancers ([@bib55]), suggesting a more general role in the transcriptional regulation of SOX10. While OLIG2 is an important regulator of this system, we do not observe an upregulation of *Olig2* upon VPA+T3 treatment or *Hdac2* and/or *Hdac3* siRNA in NSCs and Oli-neu cells, respectively ([Figures S3](#app3){ref-type="sec"}G and S3I). It will be of immediate interest to elucidate additional factors responsible for HDAC2 recruitment to the U2 enhancer in NSCs and prenatal oligodendrocyte progenitors. Indeed, since *Sox2* knockdown failed to induce a significant increase in *Sox10* expression even in the presence of T3, it is plausible that other class B1 Sox factors such as SOX1/3 could be involved, and the role for class B2 factors binding similar sequences but with alternative actions, such as SOX14 or SOX21, should be further investigated.

In postnatal OPCs, increased levels of SOX10 seem to repress *Sox2* expression and consequently promote late progression of oligodendrocyte differentiation. Intriguingly, forced *Sox2* expression mediates dedifferentiation of maturely differentiated oligodendrocytes ([@bib26; @bib27]) and SOX9 has been shown to promote neural stem cell state ([@bib44]). Whereas there are few previous demonstrations of such key factors maintaining differentiated state in the central nervous system, the requirement of SOX10 for retaining a more differentiated state partly resembles the master role of PAX5 maintaining the differentiated state of mature B lymphocytes ([@bib7]). Our present observations that SOX10 is required for repression of *Sox2* and *Sox9* in late oligodendrocyte precursor cells, in addition to the distinct requirements for NCOR, SMRT, and HDAC-regulated repressor actions in the progression of neural stem and progenitor differentiation, suggest a distinct order of repressor and corepressor action to mediate the serial events that details the neuronal and oligodendrocyte lineages, with expression of *Sox10* required to prevent reexpression of gene products promoting stem cell characteristics.

Experimental Procedures {#sec4}
=======================

Embryonic Neural Stem Cell Cultures {#sec4.1}
-----------------------------------

Rat embryonic neural stem cells were derived as previously described in detail elsewhere ([@bib16; @bib22; @bib24]). In brief, rat cortical tissue from embryonic day 15.5 was dissociated and 800 × 10^3^ cells were plated per 10 cm dish, previously coated with poly-L-ornithine and fibronectin (both from Sigma-Aldrich). Neural stem cells were then expanded in N2 media with 10 ng/ml of basic fibroblastic growth factor (R&D Systems) and passaged by light dissociation in the presence of HBSS, NaHCO3, and HEPES (from Invitrogen and Sigma-Aldrich). For differentiation assays, neural stem cells (passage 1) were plated at the following densities: 150 × 10^3^ cells in 35 mm plates (Corning) or 300 × 10^3^ cells in 60 mm plates (Corning). NSCs were differentiated for up to 7 DIV in the absence of FGF-2 (N2), in the presence of VPA (0.5 mM, a concentration at which it specifically inhibits class I HDACs, Sigma-Aldrich) ([@bib13]) or its vehicle 70% ethanol (EtOH), and with or without thyroid hormone (T3---50 ng/ml, Sigma-Aldrich). Factors were added daily and media was changed every second day. After 1, 3, or 7 DIV, cells were fixed with 10% formalin (Sigma-Aldrich) and analyzed by immunocytochemistry or qRT-PCR. For ChIP assays, NSCs were expanded after the first passage until confluency, without contact between adjacent colonies. Animals were treated in accordance with institutional and national guidelines, with all required ethical permits. In [Figure S2](#app3){ref-type="sec"}, FGF2 (10 ng/ml) expanded NSCs were treated for 3 DIV with FGF2 (10 ng/ml), IGF-2 (5 ng/ml), and PDGF-BB (10 ng/ml) (OPC media).

OPC Cultures {#sec4.2}
------------

The embryonic OPC cell line Oli-neu and the postnatal OPC cells were cultured as previously described ([@bib25; @bib33]); for details see [Supplemental Information](#app3){ref-type="sec"}.

Transfection-Lipofection {#sec4.3}
------------------------

siRNAs or pcDNAEF1-eGFP (Amaxa) were lipofected using Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions. Three micrograms of siRNA or 1 μg pcDNAEF1-eGFP was used per 35-mm plate. Opti-MEM I reduced serum medium was used to prepare the complexes. Cells were changed to Dulbecco\'s modified Eagle\'s medium (Invitrogen) and incubated with the complexes for 4 hr before returning to their original media. Cells were collected for immunocytochemistry or qRT-PCR analysis after 1 or 3 DIV. Lipofection of siRNA in differentiated conditions was performed after 3 DIV differentiation. The following target sequences for siRNAs (A4 synthesis, Dharmacon) were used.

### ECFP Control {#sec4.3.1}

5′-GAAGAACGGCAUCAAGGCC-3′.

### Sox10 {#sec4.3.2}

5′- CUGCUGUUCCUUCUUGACC-3 ([@bib41]).

### Hdac2 {#sec4.3.3}

\(1\) 5′-AAA UGU CGC UGA UCA UAA GAA-3′.

\(2\) 5′-AAG GUG UUC AAA UGC AAG CUA-3′.

### Hdac3 {#sec4.3.4}

\(1\) 5′-AAU AGC CUA GUC CUG CAU UAU-3′.

\(2\) 5′-AAC ACA GCU AAA CAA UAA GAU-3′

Optimal results for differentiation and gene expression in NSCs by HDAC2 and HDAC3 siRNAs were titrated to knockdowns in the range of 50%--75%. Higher efficiency resulted in increased cell death along with previous observations, and lower efficiency yielded less significant results.

Chromatin Immunoprecipitation and qPCR {#sec4.4}
--------------------------------------

ChIP-IT Express (Active Motif) was used according to the supplier's recommendations. Cells were crosslinked using 1% formaldehyde for 10 min. Cells were rinsed twice with cold PBS, collected by scraping and pelleted at 2,000 rpm for 4 min at 4°C. Frozen pelleted cells were resuspended in lysis buffer and centrifuged for 10 min at 4°C, and the pelleted nuclei were resuspended in the shearing buffer. Chromatin was then sonicated using a Bioruptor 200 (Diagenode) at high frequency, 0.5 min/0.5min, for 12 min. Sonicated chromatin was analyzed in a 3% agarose gel to confirm efficient sonication. Input was collected for further analysis. Five micrograms of chromatin was incubated for 1 hr at 4°C with protein G magnetic beads and then immunoprecipitated overnight at 4°C with the following antibodies: α-H3K9ac (07-352; Upstate, 5 μl), α-H3K14ac (06-911; Upstate, 5 μl), α-H4K16ac (07-329; Upstate, 5 μl), α-HDAC2 (sc-7899x; Santa Cruz, 5 μg), α-HDAC3 (sc-11417x; Santa Cruz, 5 μg), α-SOX2 (sc-17320x; Santa Cruz, 1 μg), RNA polymerase II (Active Motif, positive control for ChIP-IT Express, 2 μg), Histone H3 (Abcam, ab1791, 2 μg), rabbit IgG (Active Motif, negative control, 2 μg; Santa Cruz, sc-2027, 1 μg), and goat IgG (Santa Cruz, sc-2028, 1 μg). After three washes with ChIP buffer 1 and two washes with ChIP buffer 2, the IP DNA was reverse crosslinked and resuspended in a final volume of 130 μl. Purified DNA and 1% input were analyzed by qPCR, using 5-fold dilutions of the input for standard curves and triplicates per sample. When primer dimers were detected, the relative quantity for the specific sample was considered to be zero. As the standard curve method was used, potential differences in primer efficiency were taken in account and occupancy in different regulatory regions could be compared for a specific antibody.

RNA Profiling {#sec4.5}
-------------

RNA profiling was performed as previously described ([@bib21]); for details see [Supplemental Information](#app3){ref-type="sec"}.

Statistical Analysis {#sec4.6}
--------------------

Statistical analysis and graphs were performed using the software Prism 4 (Graph Pad). When comparing to a hypothetical control value (100%), one sample t test was used. When two groups were compared, statistical analysis was performed using two-tailed unpaired t test. When comparing three or more groups, one-way ANOVA analysis of variance with Bonferroni's multiple comparison test was used. Comparisons were performed between all treatments, unless stated otherwise. The threshold value for statistical significance (α value) was set at 0.05 (^∗^p \< 0.05). In all graphs, results are expressed as mean ± SEM. The "n" in the figure legends represents the number of independent experiments.

Accession Numbers {#app1}
=================

The ChIP-seq data are freely accessible in the GEO database under accession number [GSE57232](ncbi-geo:GSE57232){#intref0015}. Additional descriptions of qRT-PCR, immunocytochemistry and ChIP-seq methods can be found in the [Supplemental Information](#app3){ref-type="sec"}.
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![Single-Gene and Genome-wide ChIP Reveal Overlapping and Nonoverlapping Occupancies of HDAC2 and HDAC3 and HDAC3, but Not HDAC2, Knockdown Results in Increased Neuronal Differentiation of NSCs\
(A) Genome browser images of normalized densities of HDAC2 and HDAC3 on regions of chromosomes 3 and 7 in the vicinity of genes encoding *Cebpb*, *Ovol2*, *Hoxd4*, and *Zfp7* in cortically derived NSCs.\
(B) qPCR analysis of regions in the vicinity of *Sox8* and *Pax6* after ChIP for HDAC2 and HDAC3 in NSCs.\
(C) Immunoblotting of NSC protein lysates with antibodies to class I HDAC proteins. Molecular weights (approximately): HDAC1 and HDAC2, 60 kDa; HDAC3, 50 kDa.\
(D) Quantification of the numbers of TuJ1-positive cells after treatment with control siRNA (siECFP), siHDAC2, siHDAC3, and siHDAC2+3.\
(E) Immunofluorescence micrographs depicting NSCs stained for acetylated H3K9 after treatment with siECFP, siHDAC2, siHDAC3, and siHDAC2+3.\
(F) qPCR of the *Bdnf IV* promoter following ChIP with anti-acetyl-H3K9 and anti-acetyl-H3K14 antibodies following transfection of control (siECFP) or *Hdac3* siRNA.\
(G) qRT-PCR analysis of *Bdnf* mRNA levels following transfection with siECFP, siHDAC2, or siHDAC3.\
(H) qRT-PCR analysis of *Bdnf* mRNA levels in NSCs cultured from wild-type or *Smrt*^−/−^ embryos.\
(I) qPCR of the *Bdnf IV* promoter following ChIP with anti-SMRT and anti-HDAC3 antibodies in NSCs.\
The scale bar represents 40 μm (E). All experiments were performed in n = 3--5 independent experiments, ^∗^p \< 0.05, ^∗∗^p \< 0.01 (t test). Error bars, SEM.](gr1){#fig1}

![*Ncor*^*−/−*^ NSCs Differentiate into Oligodendrocyte-like Cells Similar to T3 Treatment, and the HDAC Inhibitor VPA Enhances the T3-Mediated Differentiation\
(A) Micrographs depicting NSCs isolated from wild-type (left panel) and *Ncor*^−/−^ (right panel) embryos following immunocytochemistry with anti-MBP antibody (n = 3 independent experiments).\
(B) RNA profiling data from *Ncor*^−/−^ NSCs after 4 DIV, displaying the enrichment of increased expression of oligodendrocyte-associated genes (n = 3 independent samples).\
(C) Quantification of MBP-positive cells in WT or *Ncor*^−/−^ NSCs at 4 DIV (n = 3--5 independent experiments).\
(D) qRT-PCR analysis of *Mbp* mRNA levels in wild-type or *Ncor*^−/−^ NSCs (n = 3--5 independent experiments).\
(E) qRT-PCR analysis of *Mbp* and *Plp* mRNA levels in NSCs treated with T3 and/or VPA. (n = 5 independent experiments, all treatments compared in each day).\
(F and G) Micrographs, and corresponding quantification, depicting expression of RIP (green) and MBP (red) proteins in NSCs following treatment with T3 and/or VPA (n = 3 independent experiments). 20× objective.\
(H) Quantification of oligodendrocyte radius following treatment of NSCs with T3 and/or VPA (n = 4 independent experiments, compared to EtOH treatment).\
Scale bars represent 40 μm (A) and 80 μm (F). Statistical analysis: one-way ANOVA analysis of variance with Bonferroni's multiple comparison test except (C) and (D) (t test); ^∗^p \< 0.05. Error bars, SEM.](gr2){#fig2}

![HDAC2 Regulates T3-Enhanced Oligodendrocyte Differentiation in NSCs\
(A and B) qRT-PCR analysis demonstrating the effects of *Hdac2* and/or *Hdac3* siRNAs on *Mbp* and *Plp* mRNA levels in NSCs before and after T3 treatment (n = 4 independent experiments).\
(C) Quantification of NSCs positive for MBP following transfection with control siRNA (ECFP) or siRNAs to *Hdac2* and/or *Hdac3* in the presence or absence of T3 relative to nuclear DAPI staining (n = 4 independent experiments).\
(D) qRT-PCR results demonstrating the effects of *Hdac2* and/or *Hdac3* siRNAs on *Mbp*, *Plp*, and *Cnpase* mRNA levels in Oli-neu cells (n = 7, compared to *ECFP* siRNA).\
(E) Immunocytochemistry of treated Oli-neu cells with MBP antibody (in red) and with DAPI (blue) counterstain.\
All experiments: n = 3--5 independent experiments. Scale bars represent 80 μm (E). Statistical analysis: one-way ANOVA analysis of variance with Bonferroni\'s multiple comparison test; ^∗^p \< 0.05. Error bars, SEM.](gr3){#fig3}

![HDAC2 Regulates *Sox10* Expression, and *Sox10* Knockdown in NSCs and Oli-neu Cells Prevents Effects of T3 and VPA on Oligodendrocyte Differentiation\
(A) qRT-PCR analysis of *Sox10* mRNA levels in NSCs treated with T3 and/or VPA.\
(B) qRT-PCR analysis of *Sox10* mRNA levels in NSCs transfected with control siRNA (ECFP) or siRNAs to *Hdac2* and/or *Hdac3* in the presence or absence of T3.\
(C) qRT-PCR analysis of *Hes5* mRNA levels in NSCs treated with T3 and/or VPA.\
(D) Quantification of NSCs expressing MBP following transfection with control siRNA (ECFP) or *Sox10* siRNAs in the presence of T3 and VPA relative to nuclear DAPI staining.\
(E) qRT-PCR demonstrating the effects of *Sox10* siRNA on expression of *Mbp*, *Plp*, *Sox8*, *Cnpase*, and *Sox9* following VPA and/or T3 treatment.\
All experiments: n = 3--5 independent experiments. Statistical analysis: one-way ANOVA analysis of variance with Bonferroni\'s multiple comparison test; ^∗^p \< 0.05. Error bars, SEM.](gr4){#fig4}

![HDAC2 Occupies Developmentally Critical Regulatory Regions of *Sox10* in NSCs, and *Sox10* Controls a More Mature Signature of Postnatal Oligodendrocyte Precursors by Repression of *Sox2* and *Sox9*\
(A) Diagram depicting some of the regulatory regions of *Mbp* (M1-M4) and *Sox10* (U1-U5) and their distance to the transcription start site.\
(B) qPCR analysis of the indicated regions of *Sox10* and *Mbp* following ChIP of HDAC2 or HDAC3. Percentage, percentage of input (1%).\
(C) qPCR of the indicated regions of *Sox10* following ChIP of acetylated H3K9, H3K14, or H4K16 from NSCs. Histone H3 is shown as a control for ChIP efficiency.\
(D) qPCR of the indicated regions after ChIP of SOX2 revealed that SOX2 is bound to the U2, but not the U1, enhancer of the *Sox10* gene.\
(E) qRT-PCR demonstrating the effects of *Sox10* siRNA and/or *Hdac2* siRNA on the expression of *Sox2*, *Sox8*, and *Sox9* in CG4 cells (postnatal OPCs) after *Sox10* RNA knockdown.\
All experiments: n = 2--3 independent experiments. Statistical analysis: one-way ANOVA analysis of variance with Bonferroni\'s multiple comparison test; ^∗^p \< 0.05. Error bars, SEM.](gr5){#fig5}

![NCOR and HDACs Play Nonredundant Roles in the Regulation of Neural Stem Cell Differentiation\
In multipotent embryonic NSCs, SMRT and HDAC3 are nonredundantly repressing neuronal differentiation, at least in part by repressing *Bdnf* expression required for the cell survival during the progression of neuronal differentiation. Astrocytic differentiation is repressed by both NCOR and SMRT. Oligodendrocyte differentiation is repressed by NCOR and HDAC2 in neural stem cells by repressing different OL-associated genes. In Oli-neu cells (prenatal oligodendrocyte progenitors), a repression of *Sox10* is maintained by HDAC2 that occupies the regulatory U2 enhancer of *Sox10*. In CG4 cells (postnatal oligodendrocyte precursors), *Sox10* is not only required for the progression of OL differentiation but also for retaining a more differentiated state by being required for efficient repression of *Sox2* along with *Sox9*, *Hes5*, and other progenitor associated genes.](gr6){#fig6}
